Anti-CD3 monoclonal antibody - BTG/Millennium

Drug Profile

Anti-CD3 monoclonal antibody - BTG/Millennium

Latest Information Update: 13 Jun 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BTG; University of Oxford
  • Class Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Rheumatoid arthritis; Transplant rejection; Type 1 diabetes mellitus

Most Recent Events

  • 16 Jul 2001 Preclinical development for Rheumatoid arthritis in United Kingdom (Unknown route)
  • 16 Jul 2001 Preclinical development for Type-1 diabetes mellitus in United Kingdom (Unknown route)
  • 26 Jan 2000 LeukoSite has been merged into Millennium Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top